BRIEF published on 11/04/2024 at 11:51, 1 year 8 months ago Acticor Biotech : Publication des résultats financiers semestriels 2024 Résultats Semestriels Biotechnologie Finance Redressement Judiciaire Glenzocimab
BRIEF published on 11/04/2024 at 11:51, 1 year 8 months ago Acticor Biotech: Publication of 2024 half-year financial results Biotechnology Finance Half-year Results Glenzocimab Judicial Recovery
PRESS RELEASE published on 11/04/2024 at 11:46, 1 year 8 months ago Informations privilégiées / Communiqué sur comptes, résultats Acticor Biotech publie ses résultats financiers semestriels 2024 et annonce le repositionnement du glenzocimab dans le traitement de l’infarctus du myocarde avec élévation du segment ST (STEMI) Résultats Financiers ACTICOR BIOTECH Glenzocimab Repositionnement Infarctus Du Myocarde
PRESS RELEASE published on 11/04/2024 at 11:46, 1 year 8 months ago Inside Information / News release on accounts, results Acticor Biotech publishes its half-year financial results for 2024, highlighting repositioning of glenzocimab in STEMI treatment, receivership proceedings extension, and shareholder approvals Repositioning Shareholder Approvals ACTICOR BIOTECH Glenzocimab Half-year Financial Results
BRIEF published on 10/11/2024 at 17:50, 1 year 8 months ago Acticor Biotech Advances Glenzocimab in Myocardial Infarction Treatment Clinical Trials Myocardial Infarction ACTICOR BIOTECH Glenzocimab Cardiovascular Treatment
BRIEF published on 10/11/2024 at 17:50, 1 year 8 months ago Acticor Biotech fait progresser le Glenzocimab dans le traitement de l'infarctus du myocarde Essais Cliniques ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde Traitement Cardiovasculaire
PRESS RELEASE published on 10/11/2024 at 17:45, 1 year 8 months ago Inside Information / Other news releases Acticor Biotech repositions glenzocimab in the treatment of myocardial infarction, evaluating efficacy and safety in phase 2 studies LIBERATE and GLORIA. Clinical trials aim to reduce infarct size and prevent complications Clinical Trials Phase 2b Myocardial Infarction ACTICOR BIOTECH Glenzocimab
PRESS RELEASE published on 10/11/2024 at 17:45, 1 year 8 months ago Informations privilégiées / Autres communiqués Repositionnement de glenzocimab dans le traitement de l'infarctus du myocarde par Acticor Biotech. Nouvelle étude de phase 2b LIBERATE et préparation de l'étude GLORIA Traitement Étude Clinique ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde
BRIEF published on 07/09/2024 at 20:50, 1 year 11 months ago Acticor Biotech Reports 2023 Financial Results Financial Report Annual Results Capital Raising ACTICOR BIOTECH Glenzocimab
BRIEF published on 07/09/2024 at 20:50, 1 year 11 months ago Acticor Biotech publie ses résultats financiers pour 2023 Résultats Annuels Rapport Financier ACTICOR BIOTECH Glenzocimab Levée De Capitaux
Published on 07/03/2026 at 23:00, 1 day 2 hours ago Eagle Plains Partner Refined Energy Announces Final Results for Winter 2026 Drill Program at Dufferin West
Published on 07/03/2026 at 21:28, 1 day 3 hours ago Trifecta Gold Announces Closing of $1.66 Million Private Placement
Published on 07/03/2026 at 19:30, 1 day 5 hours ago Polaris Renewable Energy Announces Q2 2026 Investor Call Details
Published on 07/03/2026 at 13:30, 1 day 11 hours ago Nextech3D.ai Unveils Strategic AI Growth Roadmap Focused on Workforce Intelligence and Event Technology Innovation
Published on 07/04/2026 at 17:35, 7 hours 38 minutes ago Vantage Introduces 24/7 Gold CFD Trading with XAUUSD247
Published on 07/04/2026 at 11:01, 14 hours 11 minutes ago EQS-Adhoc: Continental AG: Continental AG Sells ContiTech Group Sector
Published on 07/04/2026 at 09:05, 16 hours 8 minutes ago Velo x McLaren Mastercard Formula 1® Team Relaunches Live Your Fandom to Bring Fans Closer to the Sport They Love
Published on 07/03/2026 at 19:00, 1 day 6 hours ago PATRIMOINE ET COMMERCE: BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE AU 30 JUIN 2026
Published on 07/03/2026 at 18:55, 1 day 6 hours ago Saudia Arabia's Mabani Aljazeera Group invests in Tatu City's Jabali Towers development
Published on 07/03/2026 at 21:49, 1 day 3 hours ago Safran annonce la fin des négociations concernant le projet d'acquisition d’Exail Technologies.
Published on 07/03/2026 at 21:49, 1 day 3 hours ago Safran announces the end of negotiations regarding the contemplated acquisition of Exail Technologies.
Published on 07/03/2026 at 18:42, 1 day 6 hours ago Total number of voting rights and shares making up the share capital at June 30, 2026
Published on 07/03/2026 at 18:36, 1 day 6 hours ago Disclosure of transactions in own shares from July 1 to July 3, 2026
